Kurokawa Kazuo, Matsuda Michiyuki
Department of Tumor Virology, Research Institute for Microbial Diseases, Osaka University, Yamadaoka, Suita-shi, Osaka 565-0871, Japan.
Mol Biol Cell. 2005 Sep;16(9):4294-303. doi: 10.1091/mbc.e04-12-1076. Epub 2005 Jun 29.
We examined the spatio-temporal activity of RhoA in migrating cells and growth factor-stimulated cells by using probes based on the principle of fluorescence resonance energy transfer. In HeLa cells migrating at a low cell density, RhoA was activated both at the contractile tail and at the leading edge. However, RhoA was activated only at the leading edge in MDCK cells migrating as a monolayer sheet. In growth factor-stimulated Cos1 and NIH3T3 cells, the activity of RhoA was greatly decreased at the plasma membrane, but remained high at the membrane ruffles in nascent lamellipodia. These observations are in agreement with the proposed role played by RhoA in stress fiber formation, but they also implicated RhoA in the regulation of membrane ruffling, the induction of which is a typical phenotype of activated Rac. In agreement with this view, dominant negative RhoA was found to inhibit membrane ruffling induced by active Rac. Furthermore, we found that Cdc42 activity was also required for high RhoA activity in membrane ruffles. Finally, we found that mDia1, but not ROCK, was stably associated with membrane ruffles. In conclusion, these results suggested that RhoA cooperates with Rac1 and Cdc42 to induce membrane ruffles via the recruitment of mDia.
我们通过使用基于荧光共振能量转移原理的探针,研究了迁移细胞和生长因子刺激细胞中RhoA的时空活性。在低密度迁移的HeLa细胞中,RhoA在收缩尾部和前沿均被激活。然而,在单层片状迁移的MDCK细胞中,RhoA仅在前沿被激活。在生长因子刺激的Cos1和NIH3T3细胞中,RhoA的活性在质膜处大幅降低,但在新生片状伪足的膜皱褶处仍保持较高水平。这些观察结果与RhoA在应力纤维形成中所起的作用一致,但也表明RhoA参与了膜皱褶的调节,而膜皱褶的诱导是活化Rac的典型表型。与此观点一致,发现显性负性RhoA可抑制活性Rac诱导的膜皱褶。此外,我们发现Cdc42活性对于膜皱褶中高RhoA活性也是必需的。最后,我们发现mDia1而非ROCK与膜皱褶稳定相关。总之,这些结果表明RhoA与Rac1和Cdc42协同作用,通过募集mDia诱导膜皱褶。
Mol Biol Cell. 2005-9
Small GTPases. 2013
MicroPubl Biol. 2025-6-9
Int J Mol Sci. 2024-10-12
Biophys Rev (Melville). 2024-10-14
Naunyn Schmiedebergs Arch Pharmacol. 2025-3